Physician profile
Michael Workman
NPI 1801098868
$113,224.05
in general payments reported to CMS, 2019-2025
11 companies · $710 in 2025
The $710 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $444 · 2020: $590 · 2021: $47K · 2022: $33K · 2023: $31K · 2024: $677 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,695.51 |
| Food and Beverage | $1,346.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $80,085.67 | 2019-2023 | |
| Abbvie INC. | $31,239.45 | 2023-2025 | Natrelle Saline-Filled Breast Implants |
| Sientra, INC. | $515.66 | 2020-2022 | |
| Mentor Worldwide LLC | $372.62 | 2019-2022 | |
| Becton, Dickinson and Company | $250.17 | 2025 | Phasix Mesh |
| Integra Lifesciences Corporation | $225.18 | 2024 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Motiva USA, LLC | $171.05 | 2025 | |
| Supernus Pharmaceuticals, INC. | $110.77 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $102.30 | 2019 | |
| Davol INC. | $101.32 | 2022-2025 | |
| Amgen INC. | $49.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Workman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.